Venlafaxine, a serotonin–norepinephrine reuptake inhibitor, has been investigated in oncology for several supportive care indications and, more recently, for potential anticancer activity. However, the available evidence remains fragmented across clinical and preclinical studies.
This systematic review aimed...
Ahmad J. Harahsheh, Zhuldyz Myrzabay, Nazym Askambayeva et al.· Frontiers in Pharmacology· 0 citations
Background/Objectives: Chemotherapy-induced cardiotoxicity is a serious complication in breast cancer treatment, particularly with anthracyclines and HER2-targeted therapy. To evaluate the association between early elevations of cardiac markers (troponin and NT-proBNP) and the development of chemotherapy-induced cardio...
Nazym Askambayeva, Zhuldyz Myrzabay, Ahmad J. Harahsheh et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.